{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:26:00Z","timestamp":1790882760383,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00520-022-06839-4","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T04:03:17Z","timestamp":1643860997000},"page":"4505-4514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Prognosis by cancer type and incidence of zoledronic acid\u2013related osteonecrosis of the jaw: a single-center retrospective study"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0077-7026","authenticated-orcid":false,"given":"Hironobu","family":"Hata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1090-3660","authenticated-orcid":false,"given":"Kenji","family":"Imamachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8199-3037","authenticated-orcid":false,"given":"Masashi","family":"Matsuzaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0220-0535","authenticated-orcid":false,"given":"Toshihisa","family":"Osanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Harabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6641-9598","authenticated-orcid":false,"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"6839_CR1","first-page":"e253","volume":"168","author":"M Capocci","year":"2017","unstructured":"Capocci M, Romeo U, Guerra F, Mannocci A, Tenore G, Annibali S, Ottolenghi L (2017) Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. Clin Ter 168:e253\u2013e257","journal-title":"Clin Ter"},{"key":"6839_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.oooo.2015.03.001","volume":"120","author":"JJ Napenas","year":"2015","unstructured":"Napenas JJ, Kujan O, Arduino PG, Sukumar S, Galvin S, Baricevic M, Costella J, Czerninski R, Peterson DE, Lockhart PB (2015) World Workshop on Oral Medicine VI: controversies regarding dental management of medically complex patients: assessment of current recommendations Oral Surg Oral Med Oral Pathol. Oral Radiol 120:207\u2013226","journal-title":"Oral Radiol"},{"key":"6839_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41413-020-0088-1","volume":"8","author":"JT Wan","year":"2020","unstructured":"Wan JT, Sheeley DM, Somerman MJ, Lee JS (2020) Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone Res 8:14","journal-title":"Bone Res"},{"key":"6839_CR4","first-page":"2684924","volume":"2018","author":"O Di Fede","year":"2018","unstructured":"Di Fede O, Panzarella V, Mauceri R, Fusco V, Bedogni A, Lo Muzio L, Sipmo Onj B, Campisi G (2018) The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018:2684924","journal-title":"Biomed Res Int"},{"key":"6839_CR5","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F, American Association of Oral and Maxillofacial Surgeons (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update. J Oral Maxillofac Surg 72:1938\u20131956","journal-title":"J Oral Maxillofac Surg"},{"key":"6839_CR6","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00198-012-2239-8","volume":"24","author":"M Mozzati","year":"2013","unstructured":"Mozzati M, Arata V, Gallesio G (2013) Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporos Int 24:1707\u20131712","journal-title":"Osteoporos Int"},{"key":"6839_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","volume":"35","author":"V Thumbigere-Math","year":"2012","unstructured":"Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol 35:386\u2013392","journal-title":"Am J Clin Oncol"},{"key":"6839_CR8","doi-asserted-by":"publisher","first-page":"e0201343","DOI":"10.1371\/journal.pone.0201343","volume":"13","author":"S Soutome","year":"2018","unstructured":"Soutome S, Hayashida S, Funahara M, Sakamoto Y, Kojima Y, Yanamoto S, Umeda M (2018) Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: is tooth extraction a risk factor? PLoS One 13:e0201343","journal-title":"PLoS One"},{"key":"6839_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4065\/81.8.1047","volume":"81","author":"MQ Lacy","year":"2006","unstructured":"Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA (2006) Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047\u20131053","journal-title":"Mayo Clin Proc"},{"key":"6839_CR10","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","volume":"21","author":"A Corso","year":"2007","unstructured":"Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545\u20131548","journal-title":"Leukemia"},{"key":"6839_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.canep.2014.05.005","volume":"38","author":"M Harries","year":"2014","unstructured":"Harries M, Taylor A, Holmberg L, Agbaje O, Garmo H, Kabilan S, Purushotham A (2014) Incidence of bone metastases and survival after a diagnosis of bone metastases in breast cancer patients. Cancer Epidemiol 38:427\u2013434","journal-title":"Cancer Epidemiol"},{"key":"6839_CR12","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.bjc.6601198","volume":"89","author":"JJ James","year":"2003","unstructured":"James JJ, Evans AJ, Pinder SE, Gutteridge E, Cheung KL, Chan S, Robertson JF (2003) Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer 89:660\u2013665","journal-title":"Br J Cancer"},{"key":"6839_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/1097-0142(20010101)91:1<17::AID-CNCR3>3.0.CO;2-K","volume":"91","author":"AF Jacobson","year":"2001","unstructured":"Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD (2001) Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 91:17\u201324","journal-title":"Cancer"},{"key":"6839_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","volume":"65","author":"GR Pond","year":"2014","unstructured":"Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ (2014) The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 65:3\u20136","journal-title":"Eur Urol"},{"key":"6839_CR15","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2014.07.020","volume":"68","author":"G Gandaglia","year":"2015","unstructured":"Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol 68:325\u2013334","journal-title":"Eur Urol"},{"key":"6839_CR16","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/cam4.292","volume":"3","author":"H Katagiri","year":"2014","unstructured":"Katagiri H, Okada R, Takagi T, Takahashi M, Murata H, Harada H, Nishimura T, Asakura H, Ogawa H (2014) New prognostic factors and scoring system for patients with skeletal metastasis. Cancer Med 3:1359\u20131367","journal-title":"Cancer Med"},{"key":"6839_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12885-015-1396-5","volume":"15","author":"A Piccioli","year":"2015","unstructured":"Piccioli A, Spinelli MS, Forsberg JA, Wedin R, Healey JH, Ippolito V, Daolio PA, Ruggieri P, Maccauro G, Gasbarrini A, Biagini R, Piana R, Fazioli F, Luzzati A, Di Martino A, Nicolosi F, Camnasio F, Rosa MA, Campanacci DA, Denaro V, Capanna R (2015) How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease-decision analysis and comparison of three international patient populations. BMC Cancer 15:424","journal-title":"BMC Cancer"},{"key":"6839_CR18","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s11999-016-5187-3","volume":"475","author":"JA Forsberg","year":"2017","unstructured":"Forsberg JA, Wedin R, Boland PJ, Healey JH (2017) Can we estimate short- and intermediate-term survival in patients undergoing surgery for metastatic bone disease? Clin Orthop Relat Res 475:1252\u20131261","journal-title":"Clin Orthop Relat Res"},{"key":"6839_CR19","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s11999-017-5389-3","volume":"475","author":"K Ogura","year":"2017","unstructured":"Ogura K, Gokita T, Shinoda Y, Kawano H, Takagi T, Ae K, Kawai A, Wedin R, Forsberg JA (2017) Can a multivariate model for survival estimation in skeletal metastases (PATHFx) be externally validated using Japanese patients? Clin Orthop Relat Res 475:2263\u20132270","journal-title":"Clin Orthop Relat Res"},{"key":"6839_CR20","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/CORR.0000000000001081","volume":"478","author":"AB Anderson","year":"2020","unstructured":"Anderson AB, Wedin R, Fabbri N, Boland P, Healey J, Forsberg JA (2020) External validation of PATHFx version 3.0 in patients treated surgically and nonsurgically for symptomatic skeletal metastases. Clin Orthop Relat Res 478:808\u2013818","journal-title":"Clin Orthop Relat Res"},{"key":"6839_CR21","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","volume":"26","author":"T van Cann","year":"2018","unstructured":"van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Debruyne PR, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei AJF, Punie K, Wildiers H, Beuselinck B (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26:869\u2013878","journal-title":"Support Care Cancer"},{"key":"6839_CR22","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.4317\/medoral.22858","volume":"24","author":"C Vallina","year":"2019","unstructured":"Vallina C, Ramirez L, Torres J, Casanas E, Hernandez G, Lopez-Pintor RM (2019) Osteonecrosis of the jaws produced by sunitinib: a systematic review. Med Oral Patol Oral Cir Bucal 24:e326\u2013e338","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"6839_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.oooo.2017.10.010","volume":"125","author":"H Abel Mahedi Mohamed","year":"2018","unstructured":"Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M (2018) Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 125:157\u2013163","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6839_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/jrpp.JRPP_17_36","volume":"6","author":"F Ashrafi","year":"2017","unstructured":"Ashrafi F, Derakhshandeh A, Movahedian B, Moghaddas A (2017) Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: a case report. J Res Pharm Pract 6:182\u2013185","journal-title":"J Res Pharm Pract"},{"key":"6839_CR25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","volume":"113","author":"Y Fleissig","year":"2012","unstructured":"Fleissig Y, Regev E, Lehman H (2012) Sunitinib related osteonecrosis of jaw: a case report Oral Surg Oral Med Oral Pathol. Oral Radiol 113:e1-3","journal-title":"Oral Radiol"},{"key":"6839_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","volume":"113","author":"O Nicolatou-Galitis","year":"2012","unstructured":"Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, Raber-Durlacher JE, Dimitriadis G, Dimopoulos MA (2012) Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 113:234\u2013238","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"6839_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","volume":"15","author":"FP Koch","year":"2011","unstructured":"Koch FP, Walter C, Hansen T, Jager E, Wagner W (2011) Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15:63\u201366","journal-title":"Oral Maxillofac Surg"},{"key":"6839_CR28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","volume":"110","author":"S Hoefert","year":"2010","unstructured":"Hoefert S, Eufinger H (2010) Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:463\u2013469","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"6839_CR29","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","volume":"466","author":"H Sugiura","year":"2008","unstructured":"Sugiura H, Yamada K, Sugiura T, Hida T, Mitsudomi T (2008) Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res 466:729\u2013736","journal-title":"Clin Orthop Relat Res"},{"key":"6839_CR30","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, Garcia-Saenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I (2012) Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol 7:1823\u20131829","journal-title":"J Thorac Oncol"},{"key":"6839_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00432-014-1853-6","volume":"141","author":"TI Gabbert","year":"2015","unstructured":"Gabbert TI, Hoffmeister B, Felsenberg D (2015) Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol 141:749\u2013758","journal-title":"J Cancer Res Clin Oncol"},{"key":"6839_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181\u2013188","journal-title":"Breast Cancer Res Treat"},{"key":"6839_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3109\/00365590903295193","volume":"43","author":"A Haidar","year":"2009","unstructured":"Haidar A, Jonler M, Folkmar TB, Lund L (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 43:442\u2013444","journal-title":"Scand J Urol Nephrol"},{"key":"6839_CR34","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1248\/bpb.b15-00385","volume":"38","author":"M Kajizono","year":"2015","unstructured":"Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J, Sendo T (2015) Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 38:1850\u20131855","journal-title":"Biol Pharm Bull"},{"key":"6839_CR35","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","volume":"65","author":"T Mavrokokki","year":"2007","unstructured":"Mavrokokki T, Cheng A, Stein B, Goss A (2007) Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415\u2013423","journal-title":"J Oral Maxillofac Surg"},{"key":"6839_CR36","first-page":"109","volume":"77","author":"E Merigo","year":"2006","unstructured":"Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D\u2019Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77:109\u2013117","journal-title":"Acta Biomed"},{"key":"6839_CR37","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1634\/theoncologist.2009-0115","volume":"14","author":"PK Palaska","year":"2009","unstructured":"Palaska PK, Cartsos V, Zavras AI (2009) Bisphosphonates and time to osteonecrosis development. Oncologist 14:1154\u20131166","journal-title":"Oncologist"},{"key":"6839_CR38","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1158\/1078-0432.CCR-14-0434","volume":"20","author":"CG Patel","year":"2014","unstructured":"Patel CG, Yee AJ, Scullen TA, Nemani N, Santo L, Richardson PG, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Raje NS (2014) Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res 20:3955\u20133961","journal-title":"Clin Cancer Res"},{"key":"6839_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1601-0825.2005.01130.x","volume":"11","author":"FR Pires","year":"2005","unstructured":"Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, Correa ME, Almeida JP, Alves Fde A, Lopes MA, de Almeida OP (2005) Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 11:365\u2013369","journal-title":"Oral Dis"},{"key":"6839_CR40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12663-014-0707-8","volume":"14","author":"GD Rabelo","year":"2015","unstructured":"Rabelo GD, Assuncao JN Jr, Chavassieux P, Soares HA, Alves FA, Lemos CA Jr (2015) Bisphosphonate-related osteonecrosis of the jaws and its array of manifestations. J Maxillofac Oral Surg 14:699\u2013705","journal-title":"J Maxillofac Oral Surg"},{"key":"6839_CR41","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2015.04.032","volume":"68","author":"F Saad","year":"2015","unstructured":"Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ (2015) Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol 68:570\u2013577","journal-title":"Eur Urol"},{"key":"6839_CR42","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1210\/jc.2015-1794","volume":"100","author":"W Sim Ie","year":"2015","unstructured":"Sim Ie W, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR (2015) Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. J Clin Endocrinol Metab 100:3887\u20133893","journal-title":"J Clin Endocrinol Metab"},{"key":"6839_CR43","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.4317\/medoral.20092","volume":"20","author":"C Vidal-Real","year":"2015","unstructured":"Vidal-Real C, Perez-Sayans M, Suarez-Penaranda JM, Gandara-Rey JM, Garcia-Garcia A (2015) Osteonecrosis of the jaws in 194 patients who have undergone intravenous bisphosphonate therapy in Spain. Med Oral Patol Oral Cir Bucal 20:e267-272","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"6839_CR44","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00520-006-0120-z","volume":"15","author":"C Walter","year":"2007","unstructured":"Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15:197\u2013202","journal-title":"Support Care Cancer"},{"key":"6839_CR45","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","volume":"37","author":"N Yarom","year":"2019","unstructured":"Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP (2019) Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO Clinical Practice Guideline. J Clin Oncol 37:2270\u20132290","journal-title":"J Clin Oncol"},{"key":"6839_CR46","doi-asserted-by":"crossref","unstructured":"Hallmer F, Bjarnadottir O, Gotrick B, Malmstrom P, Andersson G (2020) Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 130:252\u2013257","DOI":"10.1016\/j.oooo.2020.04.808"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06839-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06839-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T11:08:51Z","timestamp":1659352131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06839-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6839"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06839-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-732812\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed on human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This single-center, retrospective, observational study protocol and patient information were approved by the Hokkaido Cancer Center Hospital Ethics Review Board (clinical study number 02\u201310), and informed consent was waived by this board because of the retrospective design of the study. Permission to access raw data from hospital cancer registries for life prognosis survey was also granted by the ethics review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}